Abstract
Background Previous studies in European populations have identified a large number of genetic variants affecting plasma levels of Olink proteins, but little is known about the non-genetic factors influencing plasma levels of proteins, particularly in Chinese populations.
Methods We measured plasma levels of 2,923 proteins, using Olink Explore platform, in 2,006 participants in the China Kadoorie Biobank. Linear regression analyses were used to assess the cross-sectional associations of individual proteins with 37 exposures across multiple domains (e.g. socio-demographic, lifestyle, environmental, sample processing, reproductive factors, clinical measurements, and health-related indices), adjusted for potential confounders and multiple testing. These were further replicated and compared with similar analyses in Europeans.
Results Overall 31 exposures were associated with at least one protein, with age (n=1,154), sex (n=827), BMI (n=869) showing the highest number of associations, followed by frailty index (n=597), SBP (n=479), RPG (n=387), ambient temperature (n=292), and HBsAg-positivity (n=282), with diet and physical activity showing little associations. Likewise, of the 2,923 proteins examined, 65% were associated with at least one exposure, with three proteins (CDHR2, CKB, and PLAT) showing the largest number of associations with baseline characteristics (n=14). The patterns of associations differed by sex, chiefly due to differences in lifestyle and reproductive factors. Over 90% of proteomic associations with key exposures in the current study were replicated in the UK Biobank.
Conclusions In Chinese adults, the exposome-wide assessment of Olink proteins identified a large number of associations with a wide range of exposures, which could inform future research priorities and analytic strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The funding body for the baseline survey was the Kadoorie Charitable Foundation, Hong Kong, China and the funding sources for the long-term continuation of the study include UK Wellcome Trust (202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z), Chinese National Natural Science Foundation (81390540, 81390541, 81390544), and the National Key Research and Development Program of China (2016YFC0900500, 2016YFC0900501, 2016YFC0900504, 2016YFC1303904). Core funding was provided to the CTSU, University of Oxford, by the British Heart Foundation, the UK Medical Research Council, and Cancer Research UK. The long-term follow-up was funded in part by the UK Wellcome Trust (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z). The proteomic assays were supported by BHF (FS/18/23/33512), Novo Nordisk, Olink, SomaScan and NDPH. Analyses using UK Biobank data were performed using data from this application number 50474.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The CKB complies with all required ethical standards for medical research on human subjects. Ethical approval was obtained from the Ethical Review Committee of the Chinese Centre for Disease Control and Prevention (Beijing, China, 005/2004) and the Oxford Tropical Research Ethics Committee, University of Oxford (UK, 025-04).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Data Availability
Data from baseline, first and second resurveys, and disease follow-up are available under the China Kadoorie Biobank Open Access Data Policy to bona fide researchers. Details of the China Kadoorie Biobank Data Sharing Policy are available at www.ckbiobank.org.
Abbreviations
- ACP5
- Tartrate-resistant acid phosphatase type 5
- ACRV1
- Acrosomal protein SP-10
- ALPP
- ALPP alkaline phosphatase, placental
- BMI
- Body mass index
- CDHR2
- Cadherin-related family member 2
- CGA
- Glycoprotein hormones alpha chain
- CHI3L1
- Chitinase-3-like protein 1
- CHRDL2
- Chordin-like 2
- CKB
- China Kadoorie Biobank
- CK-BB
- Brain-type creatine kinase also known as creatine kinase B-type
- CRISP2
- Cysteine-rich secretory protein 2
- CSF3
- Granulocyte colony-stimulating factor receptor
- CTSV
- Cathepsin V
- CVD
- Cardiovascular disease
- CXCL17
- C-X-C motif chemokine 17
- DPP4
- Dipeptidyl peptidase-4
- DPT
- Dermatopontin
- EDA2R
- Tumor necrosis factor receptor superfamily member 27
- EDDM3B
- Epididymal secretory protein E3-beta
- EGFR
- Epidermal growth factor receptor
- ELN
- Elastin
- Exhaled CO
- Exhaled carbon monoxide
- FABP4
- Fatty acid-binding protein, adipocyte
- FGF5
- Fibroblast growth factor 5
- FSHB
- Follitropin subunit beta
- GDF15
- Growth/differentiation factor 15
- GGT1
- Glutathione hydrolase 1 proenzyme
- GIP
- Gastric inhibitory polypeptide
- HbA1c
- Hemoglobin A1c
- HBsAg
- Hepatitis B virus surface antigen
- HSPB6
- Heat shock protein beta-6
- IGFBP2
- Insulin-like growth factor-binding protein 2
- IGFBP3
- Insulin-like growth factor-binding protein 3
- IGSF9
- Protein turtle homolog A
- IHD
- Ischaemic heart disease
- IL17D
- Interleukin-17D
- IL1RN
- Interleukin-1 receptor antagonist
- INSL3
- Insulin-like 3
- ITGB5
- Integrin beta-5
- ITIH4
- Inter-alpha-trypsin inhibitor heavy chain H4
- LAMP3
- Lysosome-associated membrane glycoprotein 3
- LEP
- Leptin
- LPL
- Lipoprotein lipase
- LRP1
- Low-density lipoprotein receptor-related protein 1
- LTBP2
- Latent-transforming growth factor beta-binding protein 2
- MAMDC4
- MAM domain-containing 4
- MELTF
- Melanotransferrin
- NPX
- Normalized Protein eXpression
- PAEP
- Glycodelin
- PLAT
- Plasminogen activator, tissue type
- PON2
- Serum paraoxonase/arylesterase 2
- pQTLs
- Protein quantitative trait locus
- QC
- Quality control
- REN
- Renin
- RPG
- Random plasma glucose
- SBP
- Systolic blood pressure
- SD
- Standard deviation
- SDK2
- Protein sidekick-2
- SHBG
- Sex hormone-binding globulin
- SNED1
- Sushi, nidogen and EGF-like domain-containing protein 1
- SPINK 6
- Serine protease inhibitor Kazal-type 6
- TEX101
- Testis-expressed protein 101
- TIMP4
- Metalloproteinase inhibitor 4
- VWA1
- Von Willebrand factor A domain containing 1
- XG
- Glycoprotein Xg